Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 8;13:974825. doi: 10.3389/fphys.2022.974825

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Yao, Li, Wang, Yang and Ma.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Compound C exacerbates the lipid metabolism disorders induced by PO in primary chicken hepatocytes. The primary chicken hepatocytes were pre-treated with/without 10 μM AMPK inhibitor compound C for 1 h, and then stimulated with/without 0.75 mmol PO for another 24 h. (A) Photography of lipid droplet accumulation by Nile Red staining (scale bars, 100 μm); (B) Relative of lipid droplet content; (C) Triglyceride (TG) content; (D) Total cholesterol (TC) content; (E) Fatty acid translocase (CD36) mRNA levels; (F) Sterol regulatory element binding protein 1c (SREBP-1c) mRNA levels; (G) Acetyl-CoA carboxylase α (ACCα) mRNA levels; (H) Fatty acid synthase (FASN) mRNA levels; (I) Peroxisome proliferator activated receptor α (PPARα) mRNA levels; (J) Carnitine palmitoyl transterase-1 (CPT-1) mRNA levels. Values represent the means ± SE. *p < 0.05 and **p < 0.01, significantly different between the indicated treatment groups.